Abstract
The aim of the study was to evaluate the pharmacokinetics of cytosine arabinoside (Ara-C) and its extracellular metabolite uracil arabinoside Ara-U in patients with acute myelogeneous leukemia (AML) in correlation to response in therapy. There are few data [4] that indicate that high and long-lasting Ara-U plasma levels increase the incorportion of Ara-C into DNA and decrease the catabolism of Ara-C, and might also play a role in getting a response in therapy. We therefore investigated the pharmacokinetics of Ara-C and Ara-U in plasma of 17 patients with AML.KeywordsAcute Myelogeneous LeukemiaKinetic CurfCytosine ArabinosideArea Under CurveUracil ArabinosideThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
